PMID- 26142166
OWN - NLM
STAT- MEDLINE
DCOM- 20160509
LR  - 20191210
IS  - 1573-7322 (Electronic)
IS  - 1382-4147 (Linking)
VI  - 20
IP  - 5
DP  - 2015 Sep
TI  - A real-world perspective on the prevalence and treatment of heart failure with a 
      reduced ejection fraction but no specific or only mild symptoms.
PG  - 545-52
LID - 10.1007/s10741-015-9496-5 [doi]
AB  - Heart failure (HF) is commonly described according to the severity of symptoms, 
      using the New York Heart Association (NYHA) classification, and the assessment of 
      ventricular function, by measuring the left ventricular ejection fraction (LVEF). 
      It is important to acknowledge, however, that the severity of symptoms does not 
      systematically correlate with the level of ventricular systolic dysfunction. 
      Patients with no or only mild symptoms are still at high risk of HF-related 
      morbidity and mortality. The objective of this review was to summarize the 
      prevalence, characteristics, and treatment of patients with chronic HF and mild 
      or no symptoms and to review epidemiological data from three recent registries 
      conducted in Europe. From a clinical practice perspective, patients with a 
      reduced ejection fraction who have only mild symptoms appear to represent a group 
      of patients for whom the provision of adequate medical care is yet to be 
      optimized. While prescription of angiotensin-converting enzyme inhibitors, 
      angiotensin receptor blockers, and beta-blockers appears to be consistently high, 
      the use of mineralocorticoid receptor antagonists is more variable and does not 
      appear to be in accordance with the latest clinical guidelines. As approximately 
      half of patients with HF and a reduced LVEF have NYHA class II symptoms, 
      significant reductions in morbidity and mortality could be achieved by more 
      comprehensive treatment of this population.
FAU - Beygui, Farzin
AU  - Beygui F
AD  - Department of Cardiology, University Hospital of Caen Basse-Normandie, Caen, 
      France, beygui-f@chu-caen.fr.
FAU - Anguita, Manuel
AU  - Anguita M
FAU - Tebbe, Ulrich
AU  - Tebbe U
FAU - Comin-Colet, Josep
AU  - Comin-Colet J
FAU - Galinier, Michel
AU  - Galinier M
FAU - Bramlage, Peter
AU  - Bramlage P
FAU - Turgonyi, Eva
AU  - Turgonyi E
FAU - Lins, Katharina
AU  - Lins K
FAU - Imekraz, Lynda
AU  - Imekraz L
FAU - de Frutos, Trinidad
AU  - de Frutos T
FAU - Bohm, Michael
AU  - Bohm M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Heart Fail Rev
JT  - Heart failure reviews
JID - 9612481
RN  - 0 (Cardiovascular Agents)
SB  - IM
MH  - *Cardiovascular Agents/classification/pharmacology
MH  - Disease Management
MH  - Europe/epidemiology
MH  - *Heart Failure/diagnosis/epidemiology/physiopathology/therapy
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Patient Acuity
MH  - Patient Selection
MH  - Prevalence
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke Volume
MH  - *Ventricular Dysfunction, Left/diagnosis/physiopathology
EDAT- 2015/07/05 06:00
MHDA- 2016/05/10 06:00
CRDT- 2015/07/05 06:00
PHST- 2015/07/05 06:00 [entrez]
PHST- 2015/07/05 06:00 [pubmed]
PHST- 2016/05/10 06:00 [medline]
AID - 10.1007/s10741-015-9496-5 [doi]
PST - ppublish
SO  - Heart Fail Rev. 2015 Sep;20(5):545-52. doi: 10.1007/s10741-015-9496-5.